Immunome, Inc. expected to post a loss of 52 cents a share - Earnings Preview

Immunome

10/08/2026 12:52

Immunome, Inc. IMNM.OQ IMNM.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026
The Bothell Washington-based  company is expected to report a 95.5% decrease in revenue to $181.82 thousand from $4.02 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Immunome, Inc. is for a loss of 52 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Immunome, Inc. is $35.50, about 41.8% above its last closing price of $25.03
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.57
-0.56
-0.48
Beat
14.6
Dec. 31 2026
-0.60
-0.60
-0.76
Missed
-26.2
Sep. 30 2025
-0.57
-0.57
-0.65
Missed
-13.2​
Jun. 30 2025
-0.51
-0.53
-0.50
Beat
5.5
​​Mar. 31 2025
-0.69
-0.68
-0.52
Beat
23.7
Dec. 31 2024
-0.43
-0.58
-1.28
Missed
-121.1​
Sep. 30 2024
-0.54
-0.56
-0.78
Missed
-39.7
Jun. 30 2024
-0.43
-0.39
-0.60
Missed
-52.5
This summary was machine generated August 10 at 11:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)